Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Accumulated Expenses (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Accumulated Expenses readings, the most recent being $7.5 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 16.86% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 16.86% increase, with the full-year FY2025 number at $7.5 million, up 16.86% from a year prior.
  • Accumulated Expenses hit $7.5 million in Q4 2025 for Aligos Therapeutics, up from $5.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.8 million in Q4 2023 to a low of $3.1 million in Q1 2023.
  • Median Accumulated Expenses over the past 5 years was $7.2 million (2021), compared with a mean of $8.8 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 75.54% in 2023 and later soared 290.37% in 2024.
  • Aligos Therapeutics' Accumulated Expenses stood at $6.3 million in 2021, then surged by 153.42% to $16.0 million in 2022, then increased by 5.01% to $16.8 million in 2023, then tumbled by 62.08% to $6.4 million in 2024, then grew by 16.86% to $7.5 million in 2025.
  • The last three reported values for Accumulated Expenses were $7.5 million (Q4 2025), $5.3 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.